Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality

Keyphrases

• Acute Respiratory Distress Syndrome 33%
• Anti-IL-6 33%
• Anti-TNF Antibodies 33%
• COVID-19 66%
• COVID-19 Mortality 100%
• Critically Ill Patients 33%
• Cytokine Levels 33%
• Cytokine Release Syndrome 100%
• End-organ Damage 33%
• Inflammatory Cytokines 100%
• Interleukin-1β 33%
• Interleukin-6 33%
• Leading Causes of Death 33%
• Mechanism of Action 33%
• Mortality Rate 33%
• Potential Therapeutics 33%
• Severe Cases 33%
• Severe Disease 33%
• Severe Patients 33%
• Severely Ill Patients 33%
• Tumor Necrosis Factor-α 33%

Immunology and Microbiology

• Coronavirinae 33%
• COVID-19 100%
• Cytokine 33%
• Cytokine Release Syndrome 100%
• Interleukin 6 66%
• Interleukin-1 33%
• Mortality Rate 33%
• Proinflammatory Cytokine 100%
• Solution and Solubility 100%
• Tumor Necrosis Factor Alpha 33%
• Tumor Necrosis Factor Antibody 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adult Respiratory Distress Syndrome 33%
• Coronavirinae 33%
• Cytokine 100%
• Cytokine Release Syndrome 100%
• Disease 66%
• Interleukin 6 66%
• Mortality Rate 33%
• Tumor Necrosis Factor 33%
• Tumor Necrosis Factor Antibody 33%